{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T05:22:07Z","timestamp":1794547327753,"version":"4.9.1"},"reference-count":48,"publisher":"American Chemical Society (ACS)","issue":"19","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100005145","name":"Basic Research Program of Jiangsu Province","doi-asserted-by":"publisher","award":["BK20251750"],"award-info":[{"award-number":["BK20251750"]}],"id":[{"id":"10.13039\/501100005145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["21504034"],"award-info":[{"award-number":["21504034"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32371434"],"award-info":[{"award-number":["32371434"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangsu Provincial Medical Key Laboratory (Key Laboratory of Nuclear Medicine)"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Improving the tumor uptake and retention without compromising background clearance remains challenging for fibroblast activation protein inhibitor (FAPI) radiotracers. Current approaches usually introduce pharmacokinetic modules or reshape molecular scaffolds, increasing structural complexity and synthetic burden. Spirocyclic rigidification offers a distinct strategy by combining conformational constraint and well-defined three-dimensional geometry, yet has not been leveraged for designing FAPI radiopharmaceuticals. Herein, we synthesized FAPI-04 analogues by replacing the piperazine linker with spirocyclic diamines. All analogues were successfully 68Ga-labeled and retained FAP-specific recognition, hydrophilicity and serum stability, but differed in pharmacokinetics and imaging profiles. [68Ga]Ga-FAPI-S1 exhibited higher tumor uptake, longer tumor residence, and improved tumor-to-background contrast than [68Ga]Ga-FAPI-04 in both HT-1080-FAP and U-87 MG models. Molecular dynamics simulations revealed enhanced local protein\u2212ligand interactions without significant changes in overall complex stability. These findings support spirocyclic replacement of piperazine linker as a feasible strategy for local three-dimensional reconfiguration of quinoline-based FAPI PET tracers.<\/jats:p>","DOI":"10.1021\/acs.jmedchem.6c02453","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:03:52Z","timestamp":1790175832000},"page":"23009-23026","source":"Crossref","is-referenced-by-count":0,"title":["Spirocyclic Reconfiguration of the Piperazine Linker Improves Quinoline-Based FAPI PET Tracer Performance"],"prefix":"10.1021","volume":"69","author":[{"given":"Wei","family":"Wu","sequence":"first","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]},{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousheng","family":"Pan","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]},{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangjie","family":"Ren","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xu","sequence":"additional","affiliation":[{"name":"Nanjing University of Science & Technology , , ,","place":["Taizhou, P. R. China, 225300"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Su","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9167-2077","authenticated-orcid":true,"given":"Xinyu","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]},{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donghui","family":"Pan","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Xu","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhen","family":"Wang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongyang","family":"Chen","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6976-8526","authenticated-orcid":true,"given":"Min","family":"Yang","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]},{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8016-2277","authenticated-orcid":true,"given":"Junjie","family":"Yan","sequence":"additional","affiliation":[{"name":"Jiangsu Institute of Nuclear Medicine , , ,","place":["Wuxi, P. R. China, 214063"]},{"name":"Nanjing Medical University , , ,","place":["Nanjing, P. R. China, 211166"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"4","key":"2026100811093502700_cit1","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.7150\/thno.69475","article-title":"Fibroblast activation protein-based theranostics in cancer research: A state-of-the-art review","volume":"12","author":"Zhao","year":"2022","journal-title":"Theranostics"},{"issue":"2","key":"2026100811093502700_cit2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","article-title":"The Latest Developments in Imaging of Fibroblast Activation Protein","volume":"62","author":"Altmann","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026100811093502700_cit3","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/s41571-022-00652-y","article-title":"Radiotheranosticsin oncology: current challenges and emerging opportunities","volume":"19","author":"Bodei","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"2026100811093502700_cit4","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.220749","article-title":"FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease","volume":"306","author":"Mori","year":"2023","journal-title":"Radiology"},{"issue":"7","key":"2026100811093502700_cit5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1038\/s41568-023-00576-4","article-title":"Advances in PET imaging of cancer","volume":"23","author":"Schwenck","year":"2023","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"2026100811093502700_cit6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00259-020-04940-6","article-title":"Usefulness of [68Ga]Ga-DOTA-FAPI-04 PET\/CT in patients presenting with inconclusive [18F]FDG PET\/CT findings","volume":"48","author":"Chen","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"2026100811093502700_cit7","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","article-title":"Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein","volume":"59","author":"Lindner","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026100811093502700_cit8","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/s1470-2045(25)00299-2","article-title":"[68Ga]Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation: a single-centre, single-arm, interventional, phase 2 trial","volume":"26","author":"Pabst","year":"2025","journal-title":"Lancet Oncol."},{"issue":"19","key":"2026100811093502700_cit9","doi-asserted-by":"publisher","first-page":"4346","DOI":"10.1158\/1078-0432.ccr-22-1432","article-title":"Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"2026100811093502700_cit10","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026100811093502700_cit11","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.2967\/jnumed.123.265486","article-title":"Initial Evaluation of [18F]FAPI-74 PET for Various Histopathologically Confirmed Cancers and Benign Lesions","volume":"64","author":"Watabe","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026100811093502700_cit12","doi-asserted-by":"publisher","first-page":"938","DOI":"10.2967\/jnumed.123.267281","article-title":"68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG","volume":"65","author":"Kline","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"10","key":"2026100811093502700_cit13","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.2967\/jnumed.124.268200","article-title":"Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors","volume":"65","author":"Galbiati","year":"2024","journal-title":"J. Nucl. Med."},{"issue":"1","key":"2026100811093502700_cit14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","article-title":"Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET)","volume":"2","author":"Mori","year":"2024","journal-title":"Npj Imaging"},{"issue":"9","key":"2026100811093502700_cit15","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","article-title":"Therapeutic potential of FAPI RLT in oncology: A systematic review","volume":"15","author":"Ruzzeh","year":"2025","journal-title":"Theranostics"},{"issue":"10","key":"2026100811093502700_cit16","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"4","key":"2026100811093502700_cit17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1021\/acs.bioconjchem.6c00056","article-title":"Linker Chemistry in Radiopharmaceutical Design","volume":"37","author":"Stoddard","year":"2026","journal-title":"Bioconjugate Chem."},{"issue":"9","key":"2026100811093502700_cit18","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI Tetramers to Improve Tumor Uptake and Efficacy of FAPI Radioligand Therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026100811093502700_cit19","doi-asserted-by":"publisher","first-page":"4831","DOI":"10.1021\/acs.molpharmaceut.5c00464","article-title":"Structural Optimization of Fibroblast Activation Protein Inhibitors Through Zwitterionic and PEG Modification Strategy: Impact on Pharmacokinetics and Tumor Imaging","volume":"22","author":"Yuan","year":"2025","journal-title":"Mol. Pharm."},{"issue":"6","key":"2026100811093502700_cit20","doi-asserted-by":"publisher","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"8","key":"2026100811093502700_cit21","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1021\/acs.molpharmaceut.3c00248","article-title":"Fibroblast Activation Protein Targeting Probe with Gly-Pro Sequence for PET of Glioblastoma","volume":"20","author":"Lai","year":"2023","journal-title":"Mol. Pharm."},{"issue":"11","key":"2026100811093502700_cit22","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1007\/s00259-023-06282-5","article-title":"Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42","volume":"50","author":"Huang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"13","key":"2026100811093502700_cit23","doi-asserted-by":"publisher","first-page":"8614","DOI":"10.1021\/acs.jmedchem.3c00259","article-title":"High Affinity and FAP-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake for FAP Inhibitors","volume":"66","author":"Wang","year":"2023","journal-title":"J. Med. Chem."},{"key":"2026100811093502700_cit24","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1021\/acs.jmedchem.4c02015","article-title":"Development of [68Ga]Ga\/[177Lu]Lu-DOTA-NI-FAPI-04 Containing a Nitroimidazole Moiety as New FAPI Radiotracers with Improved Tumor Uptake and Retention","volume":"68","author":"Luo","year":"2025","journal-title":"J. Med. Chem."},{"issue":"3","key":"2026100811093502700_cit25","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"16","key":"2026100811093502700_cit26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2101852118","article-title":"An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications","volume":"118","author":"Millul","year":"2021","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"12","key":"2026100811093502700_cit27","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1039\/d1tb02651h","article-title":"Design and characterization of fibroblast activation protein targeted pan-cancer imaging agent for fluorescence-guided surgery of solid tumors","volume":"10","author":"Mukkamala","year":"2022","journal-title":"J. Mater. Chem. B"},{"issue":"22","key":"2026100811093502700_cit28","doi-asserted-by":"publisher","first-page":"24560","DOI":"10.1021\/acs.jmedchem.5c02595","article-title":"Novel Pyridine-Based Fibroblast Activation Protein-Targeted Tracers: Design, Synthesis, and PET Imaging Evaluation for Tumors","volume":"68","author":"Yu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026100811093502700_cit29","doi-asserted-by":"publisher","first-page":"6735","DOI":"10.1021\/acs.jmedchem.5c00132","article-title":"99mTc-Labeled Quinolone-Based Novel Skeletal Tracers for Tumor Visualization through Fibroblast Activation Protein","volume":"68","author":"Luo","year":"2025","journal-title":"J. Med. Chem."},{"issue":"9","key":"2026100811093502700_cit30","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1021\/acs.bioconjchem.4c00214","article-title":"Development of an FAP-Targeted PET Probe Based on a Novel Quinolinium Molecular Scaffold","volume":"35","author":"Li","year":"2024","journal-title":"Bioconjugate Chem."},{"issue":"15","key":"2026100811093502700_cit31","doi-asserted-by":"publisher","first-page":"13392","DOI":"10.1021\/acs.jmedchem.4c01295","article-title":"Molecular Evolution of Multivalent OncoFAP Derivatives with Enhanced Tumor Uptake and Prolonged Tumor Retention","volume":"67","author":"Galbiati","year":"2024","journal-title":"J. Med. Chem."},{"issue":"25","key":"2026100811093502700_cit32","doi-asserted-by":"publisher","first-page":"17517","DOI":"10.1021\/jacs.4c05854","article-title":"AquaF Building Blocks for Water-Compatible SN2 18F-Fluorination of Small-Molecule Radiotracers","volume":"146","author":"Mou","year":"2024","journal-title":"J. Am. Chem. Soc."},{"issue":"1","key":"2026100811093502700_cit33","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1038\/s41467-023-36377-4","article-title":"Radiochemistry for positron emission tomography","volume":"14","author":"Rong","year":"2023","journal-title":"Nat. Commun."},{"issue":"22","key":"2026100811093502700_cit34","doi-asserted-by":"publisher","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"RadioligandsTargeting Fibroblast Activation Protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"2026100811093502700_cit35","doi-asserted-by":"publisher","first-page":"117368","DOI":"10.1016\/j.ejmech.2025.117368","article-title":"Spirocyclic compounds as innovative tools in drug discovery for medicinal chemists","volume":"287","author":"Varela","year":"2025","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"2026100811093502700_cit36","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1021\/acs.jmedchem.0c01473","article-title":"Spirocyclic Scaffolds in Medicinal Chemistry","volume":"64","author":"Hiesinger","year":"2021","journal-title":"J. Med. Chem."},{"key":"2026100811093502700_cit37","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1039\/9781782622246-00439","article-title":"Spirocycles as Privileged Structural Motifs in Medicinal Chemistry","volume-title":"Privileged Scaffolds in Medicinal Chemistry: Design, Synthesis, Evaluation","author":"Voss","year":"2015"},{"issue":"7","key":"2026100811093502700_cit38","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1021\/jm500031w","article-title":"Extended Structure Activity Relationship and Pharmacokinetic Investigation of (4-Quinolinoyl)glycyl-2-cyanopyrrolidine Inhibitors of Fibroblast Activation Protein (FAP)","volume":"57","author":"Jansen","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"2026100811093502700_cit39","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1021\/acsmedchemlett.0c00060","article-title":"Design and Synthesis ofStyrenylcyclopropylamine LSD1 Inhibitors","volume":"11","author":"Gehling","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"issue":"15","key":"2026100811093502700_cit40","doi-asserted-by":"publisher","first-page":"16539","DOI":"10.1021\/acs.jmedchem.5c01389","article-title":"Optimized CDK19 PET Tracers: Spirocyclic-Driven Design and Prostate Cancer Imaging","volume":"68","author":"Yu","year":"2025","journal-title":"J. Med. Chem."},{"issue":"8","key":"2026100811093502700_cit41","doi-asserted-by":"publisher","first-page":"3667","DOI":"10.1021\/jm201548z","article-title":"Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds","volume":"55","author":"Yang","year":"2012","journal-title":"J. Med. Chem."},{"issue":"7","key":"2026100811093502700_cit42","doi-asserted-by":"publisher","first-page":"4952","DOI":"10.1021\/acs.jmedchem.2c02062","article-title":"Synthesis and Evaluation of 99mTc-Labeled FAP Inhibitors with Different Linkers for Imaging of Fibroblast Activation Proteins in Tumors","volume":"66","author":"Ruan","year":"2023","journal-title":"J. Med. Chem."},{"issue":"12","key":"2026100811093502700_cit43","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","article-title":"Targeting Fibroblast Activation Protein:Radiosynthesisand Preclinical Evaluation of an 18F-Labeled FAP Inhibitor","volume":"61","author":"Toms","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"16","key":"2026100811093502700_cit44","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1002\/jcc.20291","article-title":"GROMACS: fast, flexible, and free","volume":"26","author":"Van Der Spoel","year":"2005","journal-title":"J. Comput. Chem."},{"issue":"8","key":"2026100811093502700_cit45","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"issue":"40","key":"2026100811093502700_cit46","doi-asserted-by":"publisher","first-page":"10269","DOI":"10.1021\/j100142a004","article-title":"A Well-Behaved Electrostatic Potential Based Method Using Charge Restraints for Deriving Atomic Charges - the Resp Model","volume":"97","author":"Bayly","year":"1993","journal-title":"J. Phys. Chem."},{"issue":"5","key":"2026100811093502700_cit47","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/jcc.22885","article-title":"a multifunctional wavefunction analyzer","volume":"33","author":"Lu","year":"2012","journal-title":"J. Comput. Chem."},{"issue":"10","key":"2026100811093502700_cit48","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1021\/acs.jctc.1c00645","article-title":"gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS","volume":"17","author":"Valdes-Tresanco","year":"2021","journal-title":"J. Chem. Theory Comput."}],"container-title":["Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acs.jmedchem.6c02453","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/23009\/68622204\/jm6c02453.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article-pdf\/69\/19\/23009\/68622204\/jm6c02453.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:11Z","timestamp":1794543671000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/jmcmar\/article\/69\/19\/23009\/5436691\/Spirocyclic-Reconfiguration-of-the-Piperazine"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":48,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2026,9,23]]},"published-print":{"date-parts":[[2026,10,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c02453","relation":{"has-part":[{"id-type":"doi","id":"https:\/\/doi.org\/10.1021\/acs.jmedchem.6c02453.s005","asserted-by":"subject"}]},"ISSN":["0022-2623","1520-4804"],"issn-type":[{"value":"0022-2623","type":"print"},{"value":"1520-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]}}}